European Journal of Neuroscience
November 28, 2022
T. Reilly
Ketamine acts primarily through non-competitive NMDA receptor antagonism but has myriad downstream effects. Previously best known as an anaesthetic, analgesic or substance of abuse, it is now part of psychiatry’s toolkit as an anti-depressant (Price et al., 2022). Ketamine is also useful as a model of psychosis, reproducing symptoms and allowing examination of corresponding brain states. It was...
Medicine
November 25, 2022
Jiayu Xu, Manxue Mei, Haoxiang Sun et al.
Type 2 diabetes mellitus is intimately linked to chronic stress. Meditation programs belong to mind-body therapies, which could benefit patients' disease management. Though some clinical trials have proved that meditation programs have the ability to improve level of blood glucose quality of life, body mass index and blood indexes related to metabolism in individuals with type 2 diabetes...
The Journal of Clinical Psychiatry
November 23, 2022
Pierre A Geoffroy, Rodolphe Borand, Marine Ambar Akkaoui et al.
Objective: Nightmares seem to predict suicidal behaviors, and the aim of this study is to explore the chronology and trajectories of alterations in dream contents before a suicidal crisis, distinguishing 3 different experiences: bad dreams, nightmares, and suicidal scenarios during dreams. Methods: This naturalistic study included individuals hospitalized between January 2021 and May 2021 in a...
Research Square
November 22, 2022
Haifei Shen, Ri Zhang, Xiujie Zhang et al.
preprint
Abstract Purpose: To explore the moderation of mindfulness on the relationship between anxiety and somatization symptoms in middle-aged and elderly female patients with hypertension, and provide foundation for the development of more effective mindfulness intervention strategies. Methods: A total of 109 middle-aged and elderly female patients with hypertension were participated in this...
Mental Health Weekly
November 21, 2022
Gary Enos
A newly published study offers support for another viable treatment option for patients with an anxiety disorder who hesitate to take medication or aren't a good candidate for psychotherapy. The study found that eight weeks of a structured mindfulness‐based intervention was noninferior to eight weeks of anti‐depressant treatment in reducing anxiety symptoms.
International Journal of Environmental Research and Public Health
November 21, 2022
Maryam Farhang, Graciela Rojas, Pablo Martínez et al.
11 citations
BACKGROUND: There is a global agreement in the medical community that a significant proportion of dementia cases could be prevented or postponed. One of the factors behind this agreement comes from scientific evidence showing that mind-body interventions such as mindfulness and yoga for the elderly have been related to a range of positive outcomes, including improved cognition performance in...
Psychoactives
November 21, 2022
Rafael G. Dos Santos, Jaime E. C. Hallak
In the last two decades, an increasing trend has unfolded toward the possible beneficial uses of natural hallucinogenic substances for treating mental health disorders [...]
PLoS One
November 18, 2022
Mariam Mhanna, Christian-Joseph El Zouki, Abdallah Chahine et al.
Background Dissociative experiences are psychological manifestations characterized by a loss of connection and continuity between thoughts, emotions, environment, behavior, and identity. Lebanon has been facing indescribable events in the last few years, including the COVID-19 pandemic, the Beirut explosion, a crushing economic crisis with the highest inflation rate the country has known in...
Zoological Research
November 18, 2022
Rongjun Ni, Tianhao Gao, Yi-Yan Wang et al.
Ketamine, a rapid-acting antidepressant drug, has been used to treat major depressive disorder and bipolar disorder (BD). Recent studies have shown that ketamine may increase the potential risk of treatment-induced mania in patients. Ketamine has also been applied to establish animal models of mania. At present, however, the underlying mechanism is still unclear. In the current study, we found...
Neuropharmacology
November 17, 2022
Satoshi Deyama, Katsuyuki Kaneda
The neurotrophic hypothesis of depression proposes that reduced levels of brain-derived neurotrophic factor (BDNF) and vascular endothelial growth factor (VEGF) contribute to neuronal atrophy or loss in the prefrontal cortex (PFC) and hippocampus and impaired hippocampal adult neurogenesis, which are associated with depressive symptoms. Chronic, but acute, treatment with typical monoaminergic...